How can early market access professionals take a holistic approach to finding the right analogues in the right time frame?

A common challenge early market access teams face is how to ensure they are finding and analysing the right analogues.

There’s much to consider and a lot at stake, not to mention the time pressures to answer complex questions, at pace.

Often, through no fault of their own, early market access teams must make ‘best guess’ recommendations based on the analogues they already know of, rather than the entire spectrum of what’s available. It’s tough.

The good news? We’re here to help.

NURO is a tailor-built data platform that brings together Health Technology Assessment (HTA) Insights, Evidence and Pricing Intelligence, all in one place, in a format that allows for easy analogue identification.

With 450+ data points for every approved product, NURO captures the critical insights needed to support and inform key market access decisions. With insights across 30+ markets, NURO is the go-to data business intelligence solution for Global market access teams in pharma.

With insights for ~2,500 approved brands, you can learn from past launches, competitors and industry trends to predict likely HTA outcomes, price benchmarks and more for your brand.

No more cherry-picking analogues

Using 150+ filters you can perfectly match an exhaustive list of analogues in a matter of seconds, regardless of how specific your criteria. The all-in-one business intelligence platform not only provides extensive data but also connects the dots between traditionally siloed data. Discover how you can accelerate analogue analysis to better inform asset evaluation and brand strategy development.

Learn more about NURO today.